Next 10 |
MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for...
2024-03-28 08:00:08 ET Gil Blum from Needham issued a price target of $24.00 for CELC on 2024-03-28 07:08:00. The adjusted price target was set to $24.00. At the time of the announcement, CELC was trading at $18.16. CELC currently trades -4.12% versus its 52 week high of...
2024-03-27 18:40:09 ET Celcuity Inc. (CELC) Q4 2023 Earnings Conference Call March 27, 2024 4:30 p.m. ET Company Participants Maria Yonkoski - ICR Westwicke Brian Sullivan - Chief Executive Officer and Co-Founder Vicky Hahne - Chief Financial Officer Igor Gor...
2024-03-27 16:28:23 ET More on Celcuity Stifel starts Celcuity at buy, sees gedatolisib as potential blockbuster Seeking Alpha’s Quant Rating on Celcuity Historical earnings data for Celcuity Financial information for Celcuity Read the full a...
Dosed the first patient in a Phase 1b/2 trial evaluating gedatolisib in combination with darolutamide for the treatment of metastatic castration resistant prostate cancer Presented nonclinical data demonstrating the superior therapeutic effects of gedatolisib compared to other PI3K/AKT/mT...
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...
2024-03-21 10:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
MINNEAPOLIS, March 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year 2023 after the market close...
2024-03-11 08:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
MINNEAPOLIS, March 06, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Leerink Partners Global Biopharma Conference 2024 to be held in Miami on March 11-...
News, Short Squeeze, Breakout and More Instantly...
MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targ...
MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for...
2024-03-28 08:00:08 ET Gil Blum from Needham issued a price target of $24.00 for CELC on 2024-03-28 07:08:00. The adjusted price target was set to $24.00. At the time of the announcement, CELC was trading at $18.16. CELC currently trades -4.12% versus its 52 week high of...